{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:55:29Z","timestamp":1772852129702,"version":"3.50.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-21491-3","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:49:31Z","timestamp":1746438571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany"],"prefix":"10.1186","volume":"25","author":[{"given":"Katharina","family":"Schley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Jan\u00dfen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"14","key":"21491_CR1","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1017\/S0950268816001308","volume":"144","author":"JA Vazquez","year":"2016","unstructured":"Vazquez JA, Taha MK, Findlow J, Gupta S, Borrow R. Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease. Epidemiol Infect. 2016;144(14):3052\u20137.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 2","key":"21491_CR2","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3\u20139.","journal-title":"Vaccine"},{"issue":"21","key":"21491_CR3","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768\u201382.","journal-title":"Vaccine"},{"issue":"3","key":"21491_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/1871526515999150320155614","volume":"14","author":"F Dastouri","year":"2014","unstructured":"Dastouri F, Hosseini AM, Haworth E, Khandaker G, Rashid H, Booy R. Complications of serogroup B meningococcal disease in survivors: a review. Infect Disord Drug Targets. 2014;14(3):205\u201312.","journal-title":"Infect Disord Drug Targets"},{"issue":"5","key":"21491_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"21491_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774\u201383.","journal-title":"Lancet Neurol"},{"issue":"6","key":"21491_CR7","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"AB Brueggemann","year":"2021","unstructured":"Brueggemann AB, van Jansen MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, van der Linden MPG, Amin-Chowdhury Z, Bennett DE, Borrow R, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the invasive respiratory infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360\u201370.","journal-title":"Lancet Digit Health"},{"key":"21491_CR8","unstructured":"Increase in Invasive Serogroup Y Meningococcal Disease in the United States. https:\/\/emergency.cdc.gov\/han\/2024\/han00505.asp Last accessed: July 25, 2024."},{"key":"21491_CR9","unstructured":"Infections invasives \u00e0 m\u00e9ningocoque en France en. 2023. Invasive meningococcal infections in France in 2023. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/infections-invasives-a-meningocoque-en-france-en-2023#:~:text=560%20cas%20d%27IIM%20d%C3%A9clar%C3%A9s,pendant%20les%20saisons%20pr%C3%A9%2Dpand%C3%A9miques Last accessed: July 24, 2024."},{"issue":"1","key":"21491_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.","journal-title":"Popul Health Metr"},{"issue":"2 Suppl","key":"21491_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","volume":"59","author":"SI Pelton","year":"2016","unstructured":"Pelton SI. The global evolution of Meningococcal Epidemiology following the introduction of Meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3\u201311.","journal-title":"J Adolesc Health"},{"issue":"7","key":"21491_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/00325481.2020.1766265","volume":"132","author":"J Alderfer","year":"2020","unstructured":"Alderfer J, Isturiz RE, Srivastava A. Lessons from mass vaccination response to meningococcal B outbreaks at US universities. Postgrad Med. 2020;132(7):614\u201323.","journal-title":"Postgrad Med"},{"issue":"8","key":"21491_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/phar.1790","volume":"36","author":"B Atkinson","year":"2016","unstructured":"Atkinson B, Gandhi A, Balmer P. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2016;36(8):880\u201392.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"12","key":"21491_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"21491_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1080\/21645515.2018.1454570","volume":"14","author":"P Balmer","year":"2018","unstructured":"Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118\u201330.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"21491_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","volume":"15","author":"V Vetter","year":"2016","unstructured":"Vetter V, Baxter R, Denizer G, S\u00e1fadi MAP, Silfverdal S-A, Vyse A, Borrow R. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641\u201358.","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"21491_CR17","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.vaccine.2022.02.043","volume":"40","author":"S Gruhn","year":"2022","unstructured":"Gruhn S, Witte J, Greiner W, Damm O, Dietzsch M, Kramer R, Knuf M. Epidemiology and economic burden of meningococcal disease in Germany: a systematic review. Vaccine. 2022;40(13):1932\u201347.","journal-title":"Vaccine"},{"key":"21491_CR18","unstructured":"Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten. f\u00fcr 2019. Infectious disease epidemiology yearbook of notifiable diseases for 2019.https:\/\/www.rki.de\/DE\/Content\/Infekt\/Jahrbuch\/Jahrbuch_2019.pdf?__blob=publicationFile Last accessed: July 24, 2024."},{"key":"21491_CR19","unstructured":"Epidemiologisches Bulletin 36. 2022. Epidemiological Bulletin 36 2022. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2023\/Ausgaben\/04_23.pdf?__blob=publicationFile. Last accessed: July 24, 2024."},{"key":"21491_CR20","unstructured":"IMD recommendations. Empfehlungen zur Durchf\u00fchrung von Schutzimpfungen im Freistaat Sachsen. Recommendations for the implementation of vaccinations in the Free State of Saxony. https:\/\/www.slaek.de\/media\/dokumente\/patient\/gesundheitsinformationen\/impfen\/E1_2022-09-16.pdfLast accessed: July 24, 2024."},{"key":"21491_CR21","doi-asserted-by":"publisher","first-page":"1000657","DOI":"10.3389\/fped.2022.1000657","volume":"10","author":"G Pinto Cardoso","year":"2022","unstructured":"Pinto Cardoso G, Lagree-Chastan M, Caseris M, Gaudelus J, Haas H, Leroy JP, Bakhache P, Pujol JF, Werner A, Dommergues MA, et al. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 western European countries. Front Pediatr. 2022;10:1000657.","journal-title":"Front Pediatr"},{"issue":"4","key":"21491_CR22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s40121-021-00499-3","volume":"10","author":"L Soumahoro","year":"2021","unstructured":"Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MAP. Meningococcal Disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther. 2021;10(4):1949\u201388.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"21491_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","volume":"6","author":"H Campbell","year":"2022","unstructured":"Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, Ladhani SN. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6(2):96\u2013105.","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"21491_CR24","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2468-2667(17)30157-3","volume":"2","author":"MJ Knol","year":"2017","unstructured":"Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2(10):e473\u201382.","journal-title":"Lancet Public Health"},{"issue":"Suppl 1","key":"21491_CR25","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","volume":"20","author":"E Miller","year":"2001","unstructured":"Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58\u201367.","journal-title":"Vaccine"},{"issue":"23","key":"21491_CR26","first-page":"1132","volume":"147","author":"SC de Greeff","year":"2003","unstructured":"de Greeff SC, de Melker HE, Spanjaard L, van den Hof S, Dankert J. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. Ned Tijdschr Geneeskd. 2003;147(23):1132\u20135.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"Pt 7","key":"21491_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the meningococcal reference unit. J Med Microbiol. 2006;55(Pt 7):887\u201396.","journal-title":"J Med Microbiol"},{"issue":"7","key":"21491_CR28","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3201\/eid2307.170236","volume":"23","author":"H Campbell","year":"2017","unstructured":"Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency Meningococcal ACWY Vaccination Program for teenagers to Control Group W Meningococcal Disease, England, 2015\u20132016. Emerg Infect Dis. 2017;23(7):1184\u20137.","journal-title":"Emerg Infect Dis"},{"key":"21491_CR29","doi-asserted-by":"crossref","unstructured":"Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20(28).","DOI":"10.2807\/1560-7917.ES2015.20.28.21188"},{"issue":"12","key":"21491_CR30","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm M, Hahne SJM, van der Ende A, Sanders EAM, Berbers GAM, Ruijs WLM, van Sorge NM, de Melker HE, Knol MJ. Vaccine impact and effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine implementation in the Netherlands: a Nationwide Surveillance Study. Clin Infect Dis. 2022;74(12):2173\u201380.","journal-title":"Clin Infect Dis"},{"key":"21491_CR31","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1017\/S0950268823000328","volume":"151","author":"C Pardo de Santayana","year":"2023","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151:e57.","journal-title":"Epidemiol Infect"},{"key":"21491_CR32","unstructured":"SurvStat@RKI. 2.0 https:\/\/survstat.rki.de\/ Last accessed: July 25, 2024."},{"key":"21491_CR33","unstructured":"Estimated routine vaccination coverage. (\u2265\u20091 HPV vaccine dose, \u2265\u20091 Tdap, \u2265\u20091 MenACWY) among adolescents by age and birth year, National Immunization Survey-Teen, 2015\u20132021.https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/teenvaxview\/pubs-presentations\/NIS-teen-vac-coverage-estimates-2015-2021.html Last accessed: July 25, 2024."},{"key":"21491_CR34","unstructured":"Human papillomavirus (HPV) vaccination coverage in adolescents in England. 2021 to 2022.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1126762\/hpr1322-HPV2.pdf Last accessed: Jully 25, 2024."},{"key":"21491_CR35","unstructured":"Epidemiological Bulletin #49. 2021 https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/49_21.pdf?__blob=publicationFile Last accessed: July 25, 2024."},{"key":"21491_CR36","unstructured":"Donn\u00e9es de couverture vaccinale papillomavirus humains (HPV). par groupe d\u2019\u00e2ge. Human papillomavirus (HPV) vaccination coverage data by age group.https:\/\/www.santepubliquefrance.fr\/determinants-de-sante\/vaccination\/articles\/donnees-de-couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age Last accessed: July 25, 2024."},{"issue":"2","key":"21491_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martinon-Torres","year":"2022","unstructured":"Martinon-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, Abitbol V. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116(2):85\u201398.","journal-title":"Pathog Glob Health"},{"key":"21491_CR38","first-page":"3","volume":"20","author":"A Takla","year":"2022","unstructured":"Takla A, Schmid-K\u00fcpke N, Wichmann O, Rieck T. Schulimpfprogramme als L\u00f6sung Zur Steigerung Der HPV-Impfquoten in Deutschland?\u2013 Entwicklung Der Impfquoten in Einer Hessischen Modellregion Mit Schulimpfprogramm. Epid Bull. 2022;20:3\u201311.","journal-title":"Epid Bull"},{"key":"21491_CR39","unstructured":"Repr\u00e4sentativbefragungen im Studienmodul. 2 der Interventionsstudie zur Steigerung der HPV-Impfquoten in Deutschland (InveSt HPV).https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/Forschungsprojekte\/InvestHPV\/InveSt-HPV.html Last accessed: July 25, 2024."},{"issue":"5","key":"21491_CR40","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s15010-023-01978-0","volume":"51","author":"C Wahner","year":"2023","unstructured":"Wahner C, Hubner J, Meisel D, Schelling J, Zingel R, Mihm S, Wolle R, Reuschenbach M. Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic. Infection. 2023;51(5):1293\u2013304.","journal-title":"Infection"},{"key":"21491_CR41","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1186\/s12889-016-3663-z","volume":"16","author":"S Schulein","year":"2016","unstructured":"Schulein S, Taylor KJ, Konig J, Claus M, Blettner M, Klug SJ. Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health. 2016;16:995.","journal-title":"BMC Public Health"},{"issue":"9","key":"21491_CR42","doi-asserted-by":"publisher","first-page":"e0273332","DOI":"10.1371\/journal.pone.0273332","volume":"17","author":"A Sternjakob-Marthaler","year":"2022","unstructured":"Sternjakob-Marthaler A, Berko-Gottel B, Rissland J, Schope J, Taurian E, Muller H, Weber G, Lohse S, Lamberty T, Holleczek B, et al. Human papillomavirus vaccination of girls in the German model region Saarland: insurance data-based analysis and identification of starting points for improving vaccination rates. PLoS ONE. 2022;17(9):e0273332.","journal-title":"PLoS ONE"},{"issue":"10","key":"21491_CR43","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1055\/s-0042-112813","volume":"76","author":"TM Kolben","year":"2016","unstructured":"Kolben TM, Dannecker C, Baltateanu K, Goess C, Starrach T, Semmlinger A, Ditsch N, Gallwas J, Mahner S, Friese K, Kolben T. HPV Vaccination: attitude and knowledge among German gynecologists. Geburtshilfe Frauenheilkd. 2016;76(10):1074\u201380.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"8","key":"21491_CR44","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.4161\/hv.24904","volume":"9","author":"Y Delere","year":"2013","unstructured":"Delere Y, Bohmer MM, Walter D, Wichmann O. HPV vaccination coverage among women aged 18\u201320 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunother. 2013;9(8):1706\u201311.","journal-title":"Hum Vaccin Immunother"},{"key":"21491_CR45","unstructured":"Epidemiologisches Bulletin 36. 2022. Epidemiological Bulletin 36 2022. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2022\/Ausgaben\/36_22.pdf?__blob=publicationFile Last accessed: July 25, 2024."},{"key":"21491_CR46","unstructured":"Ouedraogo N, Heidt C, Schaller K. Zustimmung zur freiwilligen Schulimpfung Gegen Infektion mit humanen Papillomviren (HPV) in Deutschland. In: Nationale Impfkonferenz. Warnemunde, Rostock, Germany; 2024."},{"issue":"5","key":"21491_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/0272989X19859899","volume":"39","author":"SMN Arifin","year":"2019","unstructured":"Arifin SMN, Zimmer C, Trotter C, Colombini A, Sidikou F, LaForce FM, Cohen T, Yaesoubi R. Cost-effectiveness of alternative uses of Polyvalent Meningococcal vaccines in Niger: an Agent-based transmission modeling study. Med Decis Mak. 2019;39(5):553\u201367.","journal-title":"Med Decis Mak"},{"issue":"47","key":"21491_CR48","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck E, Klint J, Garcia S, Abbing V, Abitbol V, Akerborg O, Argante L, Bekkat-Berkani R, Hogea C, Neine M, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38(47):7558\u201368.","journal-title":"Vaccine"},{"issue":"1","key":"21491_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a Comprehensive Valuation considering the broad impact of Serogroup B Invasive Meningococcal Disease. Value Health. 2021;24(1):91\u2013104.","journal-title":"Value Health"},{"issue":"2","key":"21491_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.17269\/s41997-019-00275-4","volume":"111","author":"MC Breton","year":"2020","unstructured":"Breton MC, Huang L, Snedecor SJ, Cornelio N, Fanton-Aita F. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada. Can J Public Health. 2020;111(2):182\u201392.","journal-title":"Can J Public Health"},{"issue":"2","key":"21491_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","volume":"21","author":"H Christensen","year":"2020","unstructured":"Christensen H, Al-Janabi H, Levy P, Postma MJ, Bloom DE, Landa P, Damm O, Salisbury DM, Diez-Domingo J, Towse AK, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297\u2013309.","journal-title":"Eur J Health Econ"},{"issue":"29","key":"21491_CR52","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, Wichmann O, Hellenbrand W. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany. Vaccine. 2016;34(29):3412\u20139.","journal-title":"Vaccine"},{"issue":"2","key":"21491_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","volume":"35","author":"H Christensen","year":"2017","unstructured":"Christensen H, Trotter CL. Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England. Vaccine. 2017;35(2):208\u201311.","journal-title":"Vaccine"},{"issue":"10","key":"21491_CR54","doi-asserted-by":"publisher","first-page":"e0239926","DOI":"10.1371\/journal.pone.0239926","volume":"15","author":"GS Chung","year":"2020","unstructured":"Chung GS, Hutton DW. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. PLoS ONE. 2020;15(10):e0239926.","journal-title":"PLoS ONE"},{"issue":"7","key":"21491_CR55","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1097\/INF.0000000000001512","volume":"36","author":"P De Wals","year":"2017","unstructured":"De Wals P, Zhou Z. Cost-effectiveness comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):e203\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"21491_CR56","doi-asserted-by":"publisher","first-page":"e0175721","DOI":"10.1371\/journal.pone.0175721","volume":"12","author":"TE Delea","year":"2017","unstructured":"Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE. 2017;12(5):e0175721.","journal-title":"PLoS ONE"},{"issue":"1","key":"21491_CR57","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12916-020-01552-7","volume":"18","author":"M Domenech de Celles","year":"2020","unstructured":"Domenech de Celles M, Campbell H, Borrow R, Taha MK, Opatowski L. Transmissibility and pathogenicity of the emerging meningococcal serogroup W sequence type-11 complex south American strain: a mathematical modeling study. BMC Med. 2020;18(1):109.","journal-title":"BMC Med"},{"issue":"8","key":"21491_CR58","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","volume":"12","author":"R Gasparini","year":"2016","unstructured":"Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, Tanfani E, Bonanni P, Lucioni C, Testi A, Panatto D. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12(8):2148\u201361.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"21491_CR59","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00038-016-0821-0","volume":"61","author":"GM Ginsberg","year":"2016","unstructured":"Ginsberg GM, Block C, Stein-Zamir C. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. Int J Public Health. 2016;61(6):683\u201392.","journal-title":"Int J Public Health"},{"issue":"11","key":"21491_CR60","doi-asserted-by":"publisher","first-page":"e0188595","DOI":"10.1371\/journal.pone.0188595","volume":"12","author":"A Kuznik","year":"2017","unstructured":"Kuznik A, Iliyasu G, Lamorde M, Mahmud M, Musa BM, Nashabaru I, Obaro S, Mohammed I, Habib AG. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. PLoS ONE. 2017;12(11):e0188595.","journal-title":"PLoS ONE"},{"issue":"19","key":"21491_CR61","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","volume":"34","author":"H Lecocq","year":"2016","unstructured":"Lecocq H, Parent du Chatelet I, Taha MK, Levy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240\u201350.","journal-title":"Vaccine"},{"issue":"2","key":"21491_CR62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.amepre.2018.09.020","volume":"56","author":"IL Leeds","year":"2019","unstructured":"Leeds IL, Namasivayam V, Bamogo A, Sankhla P, Thayer WM. Cost effectiveness of Meningococcal Serogroup B Vaccination in College-aged young adults. Am J Prev Med. 2019;56(2):196\u2013204.","journal-title":"Am J Prev Med"},{"issue":"45","key":"21491_CR63","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1016\/j.vaccine.2019.09.062","volume":"37","author":"M Moura Silveira","year":"2019","unstructured":"Moura Silveira M, McBride AJA, Trotter CL. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Vaccine. 2019;37(45):6783\u20136.","journal-title":"Vaccine"},{"issue":"35","key":"21491_CR64","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1016\/j.vaccine.2019.07.008","volume":"37","author":"S Si","year":"2019","unstructured":"Si S, Zomer E, Fletcher S, Lee J, Liew D. Cost-effectiveness of meningococcal polysaccharide serogroups a, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019;37(35):5009\u201315.","journal-title":"Vaccine"},{"issue":"46","key":"21491_CR65","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1016\/j.vaccine.2019.09.060","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Haji Ali Afzali H, Giles L, Marshall H. Lifetime costs of invasive meningococcal disease: a Markov model approach. Vaccine. 2019;37(46):6885\u201393.","journal-title":"Vaccine"},{"issue":"8","key":"21491_CR66","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2021.1880209","volume":"17","author":"SV Watle","year":"2021","unstructured":"Watle SV, Naess LM, Tunheim G, Caugant DA, Wisloff T. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Hum Vaccin Immunother. 2021;17(8):2777\u201387.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"21491_CR67","doi-asserted-by":"publisher","first-page":"e1002495","DOI":"10.1371\/journal.pmed.1002495","volume":"15","author":"R Yaesoubi","year":"2018","unstructured":"Yaesoubi R, Trotter C, Colijn C, Yaesoubi M, Colombini A, Resch S, Kristiansen PA, LaForce FM, Cohen T. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: a transmission dynamic modeling study. PLoS Med. 2018;15(1):e1002495.","journal-title":"PLoS Med"},{"issue":"3","key":"21491_CR68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","volume":"34","author":"B Ultsch","year":"2016","unstructured":"Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, et al. Methods for Health Economic Evaluation of Vaccines and immunization decision frameworks: a Consensus Framework from a European vaccine Economics Community. PharmacoEconomics. 2016;34(3):227\u201344.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"21491_CR69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0272989X05284109","volume":"26","author":"CL Trotter","year":"2006","unstructured":"Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Mak. 2006;26(1):38\u201347.","journal-title":"Med Decis Mak"},{"issue":"12","key":"21491_CR70","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, Trotter C, Glennie L, Hannigan L, Coast J. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344.","journal-title":"Health Econ"},{"key":"21491_CR71","unstructured":"German Standing Committee on Vaccination. Modelling methods for predicting epidemiological and health economic effects of vaccinations\u2013 Guidance for analyses to be presented to the German Standing Committee on Vaccination (STIKO). 2016."},{"issue":"1","key":"21491_CR72","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, Meszaros K, Schneider M, Ultsch B, Greiner W. Public Health Impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Infect Dis Ther. 2022;11(1):367\u201387.","journal-title":"Infect Dis Ther"},{"key":"21491_CR73","unstructured":"Epidemiologisches Bulletin Impfstatus der Kinder und Jugendlichen in Deutschland. STIKO: Influenzaimpfungen in Der COVID- 19-Pandemie 32\/33 2020 [Epidemiological bulletin vaccination status of children and adolescents in Germany, STIKO: influenza vaccinations in the COVID- 19 pandemic 32\/33 2020] [https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2020\/Ausgaben\/32-33_20.pdf?__blob=publicationFile] Last accessed: July 25, 2024."},{"issue":"2","key":"21491_CR74","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4161\/hv.26986","volume":"10","author":"T Rieck","year":"2014","unstructured":"Rieck T, Feig M, Eckmanns T, Benzler J, Siedler A, Wichmann O. Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccin Immunother. 2014;10(2):476\u201384.","journal-title":"Hum Vaccin Immunother"},{"key":"21491_CR75","first-page":"6","volume":"49","author":"T Rieck","year":"2021","unstructured":"Rieck T, Feig M, Siedler A. Impfquoten Von Kinderschutzimpfungen in Deutschland\u2013 Aktuelle Ergebnisse Aus Der RKI-Impfsurveillance. Epid Bull. 2021;49:6\u201329.","journal-title":"Epid Bull"},{"issue":"1","key":"21491_CR76","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12879-020-05104-5","volume":"20","author":"CFC Borja-Tabora","year":"2020","unstructured":"Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infect Dis. 2020;20(1):426.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"21491_CR77","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Peyrani P, Webber C, Van Der Wielen M, Cheuvart B, De Schrevel N, Aris E, Cutler M, Li P, Perez JL. Ten-year antibody persistence and booster response to MenACWY-TT Vaccine after primary vaccination at 1\u201310 years of age. Hum Vaccin Immunother. 2020;16(6):1280\u201391.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"21491_CR78","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, Bray JE, Camara S, Rodrigues CMC, Davis K, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649. e1641-1649 e1648.","journal-title":"Clin Microbiol Infect"},{"key":"21491_CR79","unstructured":"HICP (2015\u2009=\u2009100.) - annual data (average index and rate of change) prc_hicp_aind. 2023 Average is June 2022 to May 2023. https:\/\/ec.europa.eu\/eurostat\/web\/hicp Last accessed: July 25, 2024."},{"key":"21491_CR80","volume-title":"Defeating meningitis by 2030: a global road map","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Defeating meningitis by 2030: a global road map. Geneva: World Health Organization; 2021."},{"key":"21491_CR81","unstructured":"ECDC Vaccine Scheduler. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48%26SelectedCountryIdByDisease=-1 Last accessed: July 24, 2024."},{"key":"21491_CR82","unstructured":"Meningokokken ACWY-vaccinatie. Meningococcal ACWY vaccination. https:\/\/rijksvaccinatieprogramma.nl\/vaccinaties\/menacwy Last accessed: July 25, 2024."},{"key":"21491_CR83","unstructured":"Meningococcal. the green book, Chap. 22. https:\/\/www.gov.uk\/government\/publications\/meningococcal-the-green-book-chapter-22 Last accessed: July 24, 2024."},{"key":"21491_CR84","unstructured":"Recommandation vaccinale contre les m\u00e9ningocoques des s\u00e9rogroupes A. C, W et Y. Vaccination recommendation against meningococcal serogroups A, C, W and Y.https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-03\/reommandation_vaccinale_contre_les_meningocoques_des_serogroupes_a_c_w_et_y_synthese.pdf Last accessed: July 24, 2024."},{"issue":"7","key":"21491_CR85","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1080\/21645515.2020.1855952","volume":"17","author":"L Serra","year":"2021","unstructured":"Serra L, Knuf M, Martinon-Torres F, Yi K, Findlow J. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Hum Vaccin Immunother. 2021;17(7):2205\u201315.","journal-title":"Hum Vaccin Immunother"},{"key":"21491_CR86","unstructured":"Die J1-. Untersuchung\u2013 Gesundheitscheck im Jugendalter. The J1 examination - health check in adolescence. https:\/\/www.kindergesundheit-info.de\/themen\/frueherkennung-u1-u9-und-j1\/j1-untersuchung\/ Last accessed: July 25, 2024."},{"key":"21491_CR87","doi-asserted-by":"crossref","unstructured":"Clark S, Campbell H, Mensah AA et al. An Increase in Group B Invasive Meningococcal Disease Among Adolescents and Young Adults in England Following Easing of COVID-19 Containment Measures. SSRN 2021.","DOI":"10.2139\/ssrn.3998164"},{"issue":"1","key":"21491_CR88","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","volume":"75","author":"D Danino","year":"2022","unstructured":"Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, Weinberger DM, Dagan R. Decline in Pneumococcal Disease in Young Children during the Coronavirus Disease 2019 (COVID-19) pandemic in Israel Associated with suppression of Seasonal Respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study. Clin Infect Dis. 2022;75(1):e1154\u201364.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"21491_CR89","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jval.2022.01.025","volume":"25","author":"S Ma","year":"2022","unstructured":"Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD. The impact of broader value elements on cost-effectiveness analysis: two Case studies. Value Health. 2022;25(8):1336\u201343.","journal-title":"Value Health"},{"issue":"9","key":"21491_CR90","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3201\/eid2709.204866","volume":"27","author":"S Subbarao","year":"2021","unstructured":"Subbarao S, Campbell H, Ribeiro S, Clark SA, Lucidarme J, Ramsay M, Borrow R, Ladhani S. Invasive meningococcal Disease, 2011\u20132020, and impact of the COVID-19 pandemic, England. Emerg Infect Dis. 2021;27(9):2495\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"21491_CR91","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s13104-020-05241-9","volume":"13","author":"MK Taha","year":"2020","unstructured":"Taha MK, Deghmane AE. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res Notes. 2020;13(1):399.","journal-title":"BMC Res Notes"},{"issue":"5","key":"21491_CR92","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1473-3099(06)70466-2","volume":"6","author":"JF Brundage","year":"2006","unstructured":"Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6(5):303\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"21491_CR93","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1097\/INF.0000000000003660","volume":"41","author":"M McMillan","year":"2022","unstructured":"McMillan M, Bednarz J, Leong LEX, Lawrence A, Marshall HS. Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in adolescents. Pediatr Infect Dis J. 2022;41(11):e468\u201374.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"21491_CR94","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.vaccine.2020.12.080","volume":"39","author":"M Middeldorp","year":"2021","unstructured":"Middeldorp M, van Lier A, van der Maas N, Veldhuijzen I, Freudenburg W, van Sorge NM, Sanders EAM, Knol MJ, de Melker HE. Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020. Vaccine. 2021;39(7):1039\u201343.","journal-title":"Vaccine"},{"issue":"8","key":"21491_CR95","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","volume":"28","author":"M Bertran","year":"2022","unstructured":"Bertran M, Amin-Chowdhury Z, Sheppard CL, Eletu S, Zamarreno DV, Ramsay ME, Litt D, Fry NK, Ladhani SN. Increased incidence of Invasive Pneumococcal Disease among children after COVID-19 pandemic, England. Emerg Infect Dis. 2022;28(8):1669\u201372.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"21491_CR96","doi-asserted-by":"publisher","first-page":"e045380","DOI":"10.1136\/bmjopen-2020-045380","volume":"11","author":"YH Choi","year":"2021","unstructured":"Choi YH, Miller E. Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study. BMJ Open. 2021;11(9):e045380.","journal-title":"BMJ Open"},{"key":"21491_CR97","doi-asserted-by":"publisher","first-page":"825427","DOI":"10.3389\/fcimb.2021.825427","volume":"11","author":"L Willen","year":"2021","unstructured":"Willen L, Ekinci E, Cuypers L, Theeten H, Desmet S. Infant pneumococcal carriage in Belgium not affected by COVID-19 Containment measures. Front Cell Infect Microbiol. 2021;11:825427.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"21491_CR98","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1080\/14760584.2022.2128771","volume":"21","author":"C Valmas","year":"2022","unstructured":"Valmas C, Arca E, Hensen M, Rashid H. A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries. Expert Rev Vaccines. 2022;21(11):1637\u201346.","journal-title":"Expert Rev Vaccines"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-21491-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:03:39Z","timestamp":1746439419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-21491-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21491"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-21491-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to the publication of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KS, SJ and JF are employees of Pfizer and may hold stocks or stock options. SMS and ET are employees of Evidera, an organization that provides consultancy services to multiple pharmaceutical companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1653"}}